Wave Life Sciences (NASDAQ: WVE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, WVE held its 1Q21 call. We also had the opportunity to catch up with management post the call. The most important takeaway from today’s call is that we now have a timeline as to when we can expect at least initial clinical data from Wave’s new PN-chemistry based pipeline program(s) — 2022. It’s starting to set up as potentially as a really important year for the company in our view, if they produce multiple datasets, which seems possible to us given multiple trials will begin dosing in 2021. And when we consider that Wave is pursuing rare disease of unmet need, and Wave is using adaptive design, we are starting to consider whether such trial(s) could be converted to registrational and stand on their own. Details below.”
To request access to the full report, visit https://ibn.fm/MruSz
About Wave Life Sciences Ltd.
Wave Life Sciences (NASDAQ: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.WaveLifeSciences.com and follow Wave on Twitter @WaveLifeSci.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.